Most Popular
-
1
Korea’s homegrown nanosatellite successfully launches into space
-
2
Ador CEO denies allegations, accuses Hybe of mistreating NewJeans
-
3
[Herald Interview] 'Amid aging population, Korea to invite more young professionals from overseas'
![[Herald Interview] 'Amid aging population, Korea to invite more young professionals from overseas'](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/24/20240424050844_0.jpg&u=20240424200058)
-
4
Nicaragua shuts down Seoul embassy
-
5
Hybe's multilabel system tested amid conflict with Ador
![[Herald Interview] 'Amid aging population, Korea to invite more young professionals from overseas'](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/24/20240424050844_0.jpg&u=20240424200058)
-
6
Medical reform committee kicks off despite boycott from doctors
-
7
SNU profs to suspend treatment for one day
-
8
Rocket engine expert, ex-NASA exec to lead Korea's new space agency
-
9
Over-50s, men, single-person households take up majority of those filing for bankruptcy
-
10
SK hynix pledges W20tr to ramp up DRAM production at home
[DISCLOSURE] Jeil Pharmaceutical (002620) announced on Sept. 8 that it will spin off its non-prescription medicine business division.
The new company, Jeil Health Science, will be devoted to developing new over-the-counter drugs.
Jeil Pharmaceutical will remain a public company and continue managing prescription medicine brands. The due date is Nov. 11.
By Yun Jeong-hyeon (clareyun@heraldcorp.com)
The new company, Jeil Health Science, will be devoted to developing new over-the-counter drugs.
Jeil Pharmaceutical will remain a public company and continue managing prescription medicine brands. The due date is Nov. 11.
By Yun Jeong-hyeon (clareyun@heraldcorp.com)
![[KH Explains] Korean shipbuilding stocks rally: Real growth or bubble?](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=652&simg=/content/image/2024/04/25/20240425050656_0.jpg&u=)
